ClinicalTrials.gg
RecruitingNCT05763641Updated Sep 17, 2026

TAD After Chemotherapy in Locally Advanced Breast Cancer

An observational study in Sentinel Lymph Node, Breast Cancer and Locally Advanced, sponsored by Hospital Universitari de Bellvitge. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hospital Universitari de Bellvitge · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
162
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
55th of 97
162 · median 200
Started
2021
with 53 others
Observational
97 of 905
27 open now
Primary completion
2026-12
later than 110 of 284 live
Registered
715th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 55th largest by planned enrollment of the 97 observational ones that give a count, is one of 54 that started in 2021, is one of 97 observational ones, reaches primary completion later than 110 of the 284 other live ones, and was the 715th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Read the detailed description

The procedure will consist of marking the pathological lymph node with 1 clip before the start of neoadjuvant chemotherapy (NAC) and performing surgery after completing the NAC. The TAD will include the exeresis of the node marked with a clip, and of the sentinels marked with technetium and/or patent blue, seeking to obtain at least 3 lymph nodes. Subsequently, the axillary lymphadenectomy will be completed to identify the false negative rate. An initial analysis will be carried out with the first 30 cases, and if there are more than 2 false negative cases, it will be completed until 81 cases of TAD without associated disease are obtained.

03

Conditions studied

  • Sentinel Lymph Node
  • Breast Cancer
  • Locally Advanced

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Locally advanced breast cancer tumours (cN2 or T4) after Neoadjuvant chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Axillary lymph node proven by cytology
  • Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
  • Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
  • chemotherapy

Exclusion criteria

Exclusion Criteria:

  • cN3 verified by imaging tests
  • N2 due to internal mammary involvement (N2b).
  • Tumors whose surrogate molecular subtype is luminal A.
  • Patients undergoing endocrine therapy
  • Patients with local recurrences and tumors.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
162 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • ProcedureTarget Axillary Dissection

    TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection

06

What researchers measure

Primary outcomes

  1. TAD validation in locally advanced breast cancer

    False negative rate when performing TAD after NAC

    Time frame: 3 years

Secondary outcomes

  1. Ultrasound validity to evaluate axillary response after NAC

    False-negative and positive rates of axillary ultrasound after NAC to assess lymph node response

    Time frame: 3 years

  2. MRI validity to evaluate axillary response after NAC

    False-negative and positive rates of axillary MRI after NAC to asses lymph node response

    Time frame: 3 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 70 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 10, 2023
StartActual
Feb 1, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05763641
Responsible party
Amparo Garcia-Tejedor (Clinical Professor, Hospital Universitari de Bellvitge) — Principal investigator
First posted
Mar 10, 2023
Start date
Feb 1, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Amparo García-Tejedor, MDPhD
Contact
agarciat@bellvitgehospital.cat
0034-932607702 ext. 2812
amparo Garcia-Tejedor, MDPhD
principal investigator · Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion